Home >> Healthcare >> Food & Beverage >>

Indolent Lymphoma - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 183 | Code: MRS - 35118

Indolent Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Indolent Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Indolent Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Indolent Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Indolent Lymphoma - Overview 10
Pipeline Products for Indolent Lymphoma - Comparative Analysis 11
Indolent Lymphoma - Therapeutics under Development by Companies 12
Indolent Lymphoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Indolent Lymphoma - Products under Development by Companies 15
Indolent Lymphoma - Companies Involved in Therapeutics Development 17
AbbVie Inc. 17
Altor BioScience Corporation 18
Astellas Pharma Inc. 19
Bayer AG 20
Biothera, Inc. 21
Boehringer Ingelheim GmbH 22
Celgene Corporation 23
F. Hoffmann-La Roche Ltd. 24
Gilead Sciences, Inc. 25
Incyte Corporation 26
Infinity Pharmaceuticals, Inc. 27
Juno Therapeutics Inc. 28
Kite Pharma, Inc. 29
MedImmune, LLC 30
Merck & Co., Inc. 31
Merck KGaA 32
MorphoSys AG 33
Indolent Lymphoma - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
acalisib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ALT-803 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
bendamustine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BI-836826 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CC-122 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
copanlisib hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DI-B4 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
duvelisib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
entospletinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ibrutinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
idelalisib - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Imprime PGG - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
INCB-39110 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
INCB-40093 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
INCB-50465 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
JCAR-015 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
KTE-C19 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
lenalidomide - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MEDI-0680 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
MEDI-551 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
MEDI-551 + MEDI-0680 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MOR-208 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
obinutuzumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
venetoclax - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
vorinostat - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Indolent Lymphoma - Recent Pipeline Updates 104
Indolent Lymphoma - Dormant Projects 168
Indolent Lymphoma - Discontinued Products 169
Indolent Lymphoma - Product Development Milestones 170
Featured News & Press Releases 170
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 170
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 170
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 171
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 172
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma 173
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 175
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 176
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 177
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 178
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 180
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 182
Disclaimer 183

List of Tables
Number of Products under Development for Indolent Lymphoma, H2 2015 10
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Development by Companies, H2 2015 (Contd..1) 16
Indolent Lymphoma - Pipeline by AbbVie Inc., H2 2015 17
Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2015 18
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 19
Indolent Lymphoma - Pipeline by Bayer AG, H2 2015 20
Indolent Lymphoma - Pipeline by Biothera, Inc., H2 2015 21
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 22
Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2015 23
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 24
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 25
Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2015 26
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 27
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015 28
Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 29
Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2015 30
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 31
Indolent Lymphoma - Pipeline by Merck KGaA, H2 2015 32
Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2015 33
Assessment by Monotherapy Products, H2 2015 34
Assessment by Combination Products, H2 2015 35
Number of Products by Stage and Target, H2 2015 37
Number of Products by Stage and Mechanism of Action, H2 2015 39
Number of Products by Stage and Route of Administration, H2 2015 41
Number of Products by Stage and Molecule Type, H2 2015 43
Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 104
Indolent Lymphoma - Dormant Projects, H2 2015 168
Indolent Lymphoma - Discontinued Products, H2 2015 169

List of Figures
Number of Products under Development for Indolent Lymphoma, H2 2015 10
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 14
Assessment by Monotherapy Products, H2 2015 34
Number of Products by Top 10 Targets, H2 2015 36
Number of Products by Stage and Top 10 Targets, H2 2015 36
Number of Products by Top 10 Mechanism of Actions, H2 2015 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 38
Number of Products by Top 10 Routes of Administration, H2 2015 40
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 40
Number of Products by Top 10 Molecule Types, H2 2015 42
Number of Products by Stage and Top 10 Molecule Types, H2 2015 42

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2000 View Pricing